Cyclacel Pharmaceuticals Q2 2024 GAAP EPS $(0.72) Beats $(1.44) Estimate, Sales $4.00K Miss $30.00K Estimate
Author: Benzinga Newsdesk | August 14, 2024 04:20pm
Cyclacel Pharmaceuticals (NASDAQ:
CYCC) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(1.44) by 50 percent. The company reported quarterly sales of $4.00 thousand which missed the analyst consensus estimate of $30.00 thousand by 86.67 percent. This is a 98.93 percent decrease over sales of $373.00 thousand the same period last year.
Posted In: CYCC